256 Newsroom — Uganda's Digital News Infrastructure
Business

Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Investor's Business Daily

Share
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Investor's Business Daily
Image · Investor's Business Daily

What the report says

Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.

Read the full report at Investor's Business Daily →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

Related reporting